110 related articles for article (PubMed ID: 37035109)
1. Sulfated polysaccharides act as baits to interfere with the binding of the spike protein (SARS-CoV-2) to the ACE2 receptor and can be administered through food.
Barbosa JR; de Fátima Henriques Lourenço L
J Funct Foods; 2023 May; 104():105532. PubMed ID: 37035109
[TBL] [Abstract][Full Text] [Related]
2. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
Tandon R; Sharp JS; Zhang F; Pomin VH; Ashpole NM; Mitra D; McCandless MG; Jin W; Liu H; Sharma P; Linhardt RJ
J Virol; 2021 Jan; 95(3):. PubMed ID: 33173010
[TBL] [Abstract][Full Text] [Related]
3. The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics.
Eilts F; Bauer S; Fraser K; Dordick JS; Wolff MW; Linhardt RJ; Zhang F
Carbohydr Polym; 2023 Jan; 299():120167. PubMed ID: 36876764
[TBL] [Abstract][Full Text] [Related]
4. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
5. Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve
Shiliaev N; Lukash T; Palchevska O; Crossman DK; Green TJ; Crowley MR; Frolova EI; Frolov I
J Virol; 2021 Oct; 95(21):e0135721. PubMed ID: 34406867
[TBL] [Abstract][Full Text] [Related]
6. A Sulfated Abalone Polysaccharide Inhibited SARS-CoV-2 Infection of Vero E6 Cells In Vitro.
Sun J; Song S; Ai C; Zhu B; Yang J
Foods; 2022 Sep; 11(18):. PubMed ID: 36140993
[TBL] [Abstract][Full Text] [Related]
7. Anti-SARS-CoV-2 Activity of Rhamnan Sulfate from
Song Y; He P; Rodrigues AL; Datta P; Tandon R; Bates JT; Bierdeman MA; Chen C; Dordick J; Zhang F; Linhardt RJ
Mar Drugs; 2021 Nov; 19(12):. PubMed ID: 34940684
[TBL] [Abstract][Full Text] [Related]
8. Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate.
Zhang F; He P; Rodrigues AL; Jeske W; Tandon R; Bates JT; Bierdeman MA; Fareed J; Dordick J; Linhardt RJ
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215371
[TBL] [Abstract][Full Text] [Related]
9. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
11. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
Shahbazi B; Mafakher L; Teimoori-Toolabi L
J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Development of SARS-CoV-2 Spike Interactors.
Squeglia F; Romano M; Esposito L; Barra G; Campiglia P; Sala M; Scala MC; Ruggiero A; Berisio R
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628409
[TBL] [Abstract][Full Text] [Related]
13. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
14. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
15. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
Basit A; Ali T; Rehman SU
J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
[TBL] [Abstract][Full Text] [Related]
16. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
Kim SY; Jin W; Sood A; Montgomery DW; Grant OC; Fuster MM; Fu L; Dordick JS; Woods RJ; Zhang F; Linhardt RJ
Antiviral Res; 2020 Sep; 181():104873. PubMed ID: 32653452
[TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
18. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
19. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
20. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
